Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  BioMarin Pharmaceutical Inc.    BMRN   US09061G1013

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/24/2014 07/25/2014 07/28/2014 07/29/2014 07/30/2014 Date
61.46(c) 60.6(c) 60.01(c) 61.03(c) 61.09(c) Last
923 921 955 183 894 139 639 872 1 083 663 Volume
-1.00% -1.40% -0.97% +1.70% +0.10% Change
More quotes
Company
BioMarin Pharmaceutical, Inc. develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. The company operates its business through one segment, the biopharmaceutical development and commercialization segment. Its company's product portfolio is comprised of... 
Sector
Pharmaceuticals
Calendar
07/30Earnings Release
Surperformance© rating of BioMarin Pharmaceutical In
Trading Rating : Investor Rating :
More about the company
Chart BIOMARIN PHARMACEUTICAL IN
Duration : Period :
BioMarin Pharmaceutical In Technical Analysis Chart | BMRN | US09061G1013 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 693 M
EBIT 2014 -216 M
Net income 2014 -253 M
Debt 2014 191 M
Yield 2014 -
Sales 2015 840 M
EBIT 2015 -154 M
Net income 2015 -159 M
Debt 2015 455 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 13,1x
EV / Sales 2015 11,2x
Capitalization 8 915 M
More Financials
Latest news on BIOMARIN PHARMACEUTICAL IN
1d ago BIOMARIN PHARMACEUTICAL : Patent Issued for Formulations for Lysosomal Enzymes
1d agoDJBioMarin Sells Priority Review Voucher To Regeneron
1d ago BIOMARIN PHARMACEUTICAL : Results of Operations and Financial Condition, Financi..
1d ago BioMarin Announces Second Quarter 2014 Financial Results
1d ago BIOMARIN PHARMACEUTICAL : Sells Priority Review Voucher for $67.5 Million
2d ago BIOMARIN PHARMACEUTICAL : Assigned Patent
07/23 BIOMARIN PHARMACEUTICAL : Sarah Cannon Research UK and BioMarin Collaborate on E..
07/15 BIOMARIN PHARMACEUTICAL : Assigned Patent
07/13 BIOMARIN PHARMACEUTICAL : Health Canada OKs BioMarin's Vimizim for the Treatment..
07/10 BIOMARIN PHARMACEUTICAL : Health Canada OKs BioMarin's Vimizim for the Treatment..
07/09 BIOMARIN PHARMACEUTICAL : Patent Issued for Processes of Synthesizing Dihydropyr..
07/09 BIOMARIN TO HOST SECOND QUARTER 2014 : 30pm ET
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
BioMarin Pharmaceutical In : Income Statement Evolution
More Financials
EPS Revisions
BioMarin Pharmaceutical In : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF